About Malecare

This author has not yet filled in any details.
So far Malecare has created 608 blog entries.

Decipher® Test Predicts Radiation Failure and Identifies Candidates for Early Radiation Therapy Following Prostate Surgery

Last year GenomeDx Biosciences  presented  data  showing that its Decipher® Prostate Cancer Classifier (the test), a genomic test, is capable of predicting the probability that a man will eventually develop metastatic prostate cancer, despite having surgery as a primary treatment for prostate cancer.  The company claims that the test out performs other existing tests of [...]

Comparing Surgical and Chemical Castration Side Effects for the Treatment of Prostate Cancer

Most of our testosterone is made in out testicles, so the first stage of hormone therapy to treat prostate cancer is to prevent them from making any androgens. Testosterone is said to “feed” prostate cancer, so stopping the creation of testosterone controls prostate cancer progression. We have a number of ways to limit the production [...]

By |2020-02-04T10:13:05-05:00December 24th, 2015|Advanced Prostate Cancer, Uncategorized|0 Comments

German Registry Data Analysis of Degarelix (Firmagon®) for Prostate Cance

The newest gonadotropin-releasing hormone (GnRH) antagonist therapy drug, degarelix (aka Firmagon) has become more commonly used in everyday clinical practice as an alternative hormone therapy treatment drug (ADT). Given that its use has become common it is important to understand both its safety and efficacy as compared to our older standard drugs. The best way [...]

Analyzing the Analysis – Is Surgery Superior to Radiotherapy? No, Despite the Results from A Large Canadian Study

It is a little out of the normal scope of this blog, but a recent prostate cancer study from Canada has received a lot of buzz and needs some commentary and analysis. The study concluded that for men who are diagnosed with local prostate cancer (still confined in the gland) live longer if they have [...]

NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment

NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]

Go to Top